Based on one study by Mackinnon et al., the administration of Gal-3 inhibitor TD139 in mice reduces the pathology of lung fibrosis [51] by inhibition of the SMC proliferation and migration. This evidence concerns the gene LGALS3 and pulmonary fibrosis.